Oxidative degradation of pharmaceuticals and endocrine disrupting compounds in water

Description

The dataset includes: TEM micrographs of rGO-Ag0/Fe3O4 NH. XRD patterns, FT-IR spectra, and UV-Vis absorption spectra of rGO, AgNP, and rGO-Ag0/Fe3O4 NH. X-ray photoelectron spectra of rGO and rGO-Ag0/Fe3O4 NH. Concentrations of phenol, acetaminophen, ibuprofen, naproxen, BPA, E2, and EE2 as a function of time in graphs. This dataset is associated with the following publication: Park, C.M., J. Heo, D. Wang, C. Su, and Y. Yoon. Heterogeneous activation of persulfate by reduced graphene oxide–elemental silver/magnetite nanohybrids for the oxidative degradation of pharmaceuticals and endocrine disrupting compounds in water. APPLIED CATALYSIS B: ENVIRONMENTAL. Elsevier Science Ltd, New York, NY, USA, 225: 91-99, (2018).

Resources

Name Format Description Link
33 3-7.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20Ag3d.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-7.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20Ag3d.pdf
33 3-3.%20XPS%20for%20rGO%20O1s.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-3.%20XPS%20for%20rGO%20O1s.pdf
33 2-2.%20XRD%20for%20rGO-Ag0_Fe3O4%20NH.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-2.%20XRD%20for%20rGO-Ag0_Fe3O4%20NH.pdf
33 3-5.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20C1s.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-5.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20C1s.pdf
33 3-4.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20wide.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-4.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20wide.pdf
33 3-2.%20XPS%20for%20rGO%20C1s.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-2.%20XPS%20for%20rGO%20C1s.pdf
33 2-6.%20UV-Vis%20for%20AgNP.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-6.%20UV-Vis%20for%20AgNP.pdf
33 2-5.%20UV-Vis%20for%20rGO.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-5.%20UV-Vis%20for%20rGO.pdf
33 2-1.%20XRD%20for%20rGO.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-1.%20XRD%20for%20rGO.pdf
33 1.%20TEM%20for%20rGO-Ag0_Fe3O4%20NH.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/1.%20TEM%20for%20rGO-Ag0_Fe3O4%20NH.pdf
33 2-3.%20FTIR%20for%20rGO.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-3.%20FTIR%20for%20rGO.pdf
33 3-8.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20Fe2p.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-8.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20Fe2p.pdf
33 4.%20Conc.%20of%20pollutants%20vs%20time%20in%20graphs.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/4.%20Conc.%20of%20pollutants%20vs%20time%20in%20graphs.pdf
33 3-1.%20XPS%20for%20rGO%20wide.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-1.%20XPS%20for%20rGO%20wide.pdf
33 2-7.%20UV-Vis%20for%20rGO-Ag0_Fe3O4%20NH.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-7.%20UV-Vis%20for%20rGO-Ag0_Fe3O4%20NH.pdf
33 2-4.%20FTIR%20for%20rGO-Ag0_Fe3O4%20NH.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/2-4.%20FTIR%20for%20rGO-Ag0_Fe3O4%20NH.pdf
33 3-6.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20O1s.pdf https://pasteur.epa.gov/uploads/10.23719/1521026/3-6.%20XPS%20for%20rGO-Ag0_Fe3O4%20NH%20O1s.pdf

Tags

  • nanocomposites
  • graphene-oxide
  • pharmaceuticals
  • advanced-oxidation
  • endocrine-disrupting-compounds

Topics

Categories